NICE recommends Novartis’ Mayzent on the heels of SMC approval by Lucy Parsons | Oct 15, 2020 | News | 0 Drug is licensed for secondary progressive multiple sclerosis with active disease Read More
NICE rejects Novartis’ Mayzent for secondary progressive MS by Selina McKee | Jun 26, 2020 | News | 0 NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease Read More
Novartis highlights benefits of Mayzent in MS by Selina McKee | Apr 22, 2020 | News | 0 The data underscore the advantages of early treatment initiation, the firm notes Read More
Novartis’ MS drug gets FDA approval by Anna Smith | Mar 27, 2019 | News | 0 The FDA has approved Novartis’ multiple sclerosis drug, Mayzent. Read More